U.S. markets open in 6 hours 8 minutes

Actinium Pharmaceuticals, Inc. (ATNM)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
7.70-0.05 (-0.65%)
At close: 4:00PM EDT
Sign in to post a message.
  • w
    wilfried
    Gap closed at $7.71. Up we go from here.
  • O
    Ouch
    All kidding aside, to ATNM's credit, they have been incredibly active this particular month on their twitterfeed. Incredibly informative stuff...IMO, ATNM's stock price is not gonna stay in the perpetual doghouse for too much longer...
  • O
    Ouch
    Someone should compile a list of biotechs/medtech/specialty pharma that have very late stage pipeline assets approaching imminently{~six months-to-a-year} to their phase III top-line data revelations leading up to PDUFA's/PMA's and eventual FDA decisions which, for whatever reason, the publicly traded stock has still yet to ignite or lift off(or, isn't even remotely in the ballpark of where it should be actively trading at in stock price levels given its historical time-line horizon spectrum of advancement).

    I am guessing that one of the reasons ATNM is STILL so mindbogglingly insanely cheap and obscenely miss-priced is that previous years of investors were diluted out of their positions, and so a whole new generation of radiopharm enthusiast investors have needed to replace the previous era. THIS CAN TAKE SOME TIME.... So, along with ATNM's 2020 reverse-split and multiple offerings, ATNM has had to slowly rebuild a brand new next generation of committed investors. Am I right or am I right?! This is why "being first" IS and ALWAYS WILL BE a TOTAL myth as to being one of the keys to success in biotech investing(Sorry, Tartiaboy).....

    Anyway, I will go ahead and share four still small caps that are ridiculously under-valuated, each with very late-stage asset(s), apparently with tremendous asset(s) to date with game-changing potential that STILL do not even remotely closely resemble where they should truly be currently publicly trading in stock price:

    1) ATNM
    2) AVDL
    3) VBLT
    4) XAIR

    Any more?
  • A
    Anonymous
    i took the opportunity, again, to buy more under 8, at 7.74. I will either be rewarded nicely or a big bagholder. i love the science but....come on !!
  • A
    Anonymous
    this should be $75-90 by now but isn't
  • w
    wilfried
    That M & A specialist that Actinium hired a few months ago needs to earn his keep.
  • p
    ph
    Actinium Further Strengthens Patent Portfolio with International IP Covering the Composition and Methods of Administration of Iomab-B Antibody Radiation Conjugate in the EU and Japan- connect the dots...why japan :-D
    Bullish
  • w
    wilfried
    Iomab-B patent in Japan.
    Astellas must be ready to partner and market it - or buy out ATNM.
  • T
    Tom
    Last chance to buy in or add more shares of ATNM with this great news!! It will easily surpass its $36 Price Target Estimate very soon!!! GLTA 📈
    Bullish
  • M
    Mathew Fuji
    Why aren’t the retails fearful and selling??? Why no humongous short interest buildup of shorts are so confident? Why such a pitiful volume typically used by MMs?
    I honestly am not seeing the desperation or anxiety in retail longs as much as the bashing crew says 😂
    Prove me wrong folks
    Bullish
  • O
    Ouch
    IMO, the street is currently wildly, WILDLY, miss-pricing ATNM. Such gross market inefficiency is okay while one is in their stock-accumulating-phase, but, right now, with the PHASE III SIERRA trial approaching enrollment conclusion(and then six months to topline readout), its safe to say ATNM is currently obscenely miss-priced......

    For example, APTO is only in its dosing escalation level stages of early clinical stage development, and yet it currently enjoys TWICE the market cap of ATNM!....

    Or, how about NWBO, another radiopharm play, that is essentially, like ATNM, in late-stage.....NWBO is, get this, currently almost 10(X) the market cap of ATNM(~$1.57B MC)!....

    And, its ATNM that is the biotech with the very most impressive pipeline with widest breath in potential spaces(gene/cart-t, etc) and eventual new potential standards of care.....
  • p
    ph
    at the end of the day all were hoping for data from further progressions from enrollment and 100% enrollment news. as it sits now, i expect full enrollment by the end of the year at latest and data 6 months after. the upside is the science: once this enrollment is completed with similar data to 75% enrollment, this will pop. the question isnt if, just when and the next 6 months are a good bet.
  • F
    Fuji
    Can some longs answer Oblio”s financial question regarding why institutional ownership even at this late Ph3 stage is only 12%???? I too have that question.

    Regards to his question on AML is a tough nut to crack and many fail here is my brief response-
    Again I am invested here below $8 now but My DD is relatively poor. However, from what I understand it’s an alternative and safer highly targeted myeloablative procedure for bone marrow transplants. They are projecting an exponential increase in total # of patients eligible for BMT due to the near perfect engraftment following their platform for conditioning the marrow for transplant.
    Instead of the extreme chemotherapeutic + radiation approaches this one uses radioactive Iodine linked to anti-CD45 Ab that binds tumor cells and then can be activated in a targeted localized manner in the marrow. Highly tolerable procedure with almost 100% successful engraftment and improved survivability following engraftment. Works for any hematologic malignancies AML CLL. Apparently they also have other antibodies ready that are specific to other antigens and potentially could be even applied to solid tumors? So overall their Sierra trials should open up this for a great oncologists warhead into the future to be combined with other approaches. Just me 2 cents. I think the potential is decent here and risk is low given the results we already seen from 58 patients (100% results!!) 30% post one year survival!!
    Bullish
  • O
    Ouch
    Just look at NOVN today for a tiny sampling of shareholder appreciation at the point of the phase III top-line data revelation.....Hopefully, ATNM will already be trading in the mid-$20's to mid-$30's right before the announcing of their SIERRA topline phase III for closer range of the collective PT objectives of professional analysts.....
  • A
    Anonymous
    I like this quote: I just don't hear the word curative in many drug descriptions.

    "In developing Iomab-B our goal is to improve patient outcomes by enabling potentially curative BMT for a large portion of the AML patient population."
  • S
    S2dent4lif
    Old news; results of 75% enrollment. Where is the press release about the completion of the Sierra trial? Getting tired of hearing that it's 'soon.' Tell us where you are; 85%, 90%, or 95% completed. We are investors and should be informed; not just the same results continuously repeated.
  • p
    ph
    ATNM hiring chief commercial officer..its happening! https://twitter.com/ActiniumPharma/status/1405538569742012417?s=20
    Bullish
  • O
    Ouch
    I feel safe and cozy owning a very large amount of ATNM. Seems the science is winning up to the 75% mile marker in the SIERRA trial ..Sure, the SIERRA trial needs to conclude so that the stock can get on with its continuing upward resets, but how many think that the final 25% of the SIERRA trial(which, by the way, was way back in last October's trial enrollment figure) will be any different than the previous 75%(100% conditioning success)?
  • M
    Mathew Fuji
    When you have promising data thrown at your face - It is hard to be distracted by market games for astute biotech retails. Remember times have changed. Retails are now organized, support each other and their DD is as strong or in many cases far stronger and unbiased than institutional analysts!!!!
    ATNM seems extremely promising!!!
    Bullish
  • O
    Ouch
    Which will come first for ATNM investors?

    1) 100% Iomab B trial enrollment completion
    2) The need for a walker
    3) The need for false teeth
    4) The need for Depends